InventisBio Co., Limited (SHA:688382)

Market Cap	12.34B +22.7%
Revenue (ttm)	37.29M -77.9%
Net Income	-316.87M
EPS	-0.55
Shares Out	578.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,047,529
Average Volume	21,553,792
Open	21.95
Previous Close	22.04
Day's Range	21.01 - 22.22
52-Week Range	16.56 - 49.68
Beta	0.23
RSI	50.64
Earnings Date	Apr 15, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 168
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688382

Financial Performance

In 2025, InventisBio's revenue was 37.29 million, a decrease of -77.91% compared to the previous year's 168.79 million. Losses were -316.87 million, 31.9% more than in 2024.